Mesenchymal stem cells (MSCs) are of intense therapeutic interest because they represent a population of cells that have the potential to treat a wide range of acute and degenerative diseases. MSCs are advantageous over other stem cells types for a variety of reasons. First, they avoid the ethical issues that surround embryonic stem cell research. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
Investor Demand for Cord Blood, Cord Tissue, and Perinatal Products
Did you know that more than 70% of the global cord blood market is controlled by the world’s 15 largest cord blood banking operators? It’s an incredible figure, but true.
The reason for this is that massive cord blood industry consolidation has happened in recent years, particularly within the U.S, Europe, Asia, and Latin America, with: [Read more…]
Cryo-Cell Enters Exclusive Agreement for Duke University’s Cord Blood and Tissue Assets
Cryo-Cell International, Inc. (symbol: CCEL), the world’s first private cord blood bank to separate and store stem cells, has entered into a collaborative license agreement with Duke University. The agreement grants Cryo-Cell the rights to proprietary processes and regulatory data related to cord blood and cord tissue developed at Duke.
MIAMI, Feb. 26, 2021 — Cryo-Cell plans to explore, test, and administer these treatments to patients with conditions for which there are limited FDA approved therapies, including cerebral palsy, autism, multiple sclerosis and COVID-19. [Read more…]
Alternate Ocean Offers to Acquire Largest Cord Blood Bank in China (GCBC) for $5/Share
HONG KONG, March 2, 2021 — On March 2, 2021, Global Cord Blood Corporation (GCBC) announced that it received a non-binding proposal letter from Alternate Ocean Investment Company Limited (“Alternate Ocean”), a wholly-owned subsidiary of Haitong International Securities Group Limited.
The proposal letter offers for Alternate Ocean, acting on behalf of certain funds and entities that it manages or advises, to acquire all of the outstanding ordinary shares of GCBC for US$5.00 per ordinary share in cash. [Read more…]
ReeLabs: Cord Blood Banking in India (Population 1.4 Billion)
ReeLabs is a leading cord blood bank in India. Cord blood banking in this region is of monumental importance, because the country has an astounding population of 1.4 billion. This represents an incredible 18% of the global population.
Meaning, one-out-of-every-five people on this planet lives in India and the country is now head-to-head with China as the world’s most populous country.
India’s population growth is fueled by a birth rate (19 births/1,000 population) that substantially exceeds its death rate (7.3 deaths/1,000 population).
If you’re involved with cord blood banking, you need to understand the important of this particular market and the trends emerging within it.
In this interview with Dr. Abhijit Bopardikar, Director of ReeLabs, he explains the rise of cord blood banking within India and discusses the importance of pairing stem cell therapy and research applications with stem cell storage services.
